ArticleAlzheimer's & dementia (Amsterdam, Netherlands)2017
Cerebrospinal fluid biomarkers for Alzheimer's disease in Down syndrome.
Article in Alzheimer's & dementia (Amsterdam, Netherlands), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- MALDI mass spectrometry imaging (MSI) reveals molecular and structural heterogeneity of amyloid-β in sporadic Alzheimer's disease and Down syndrome.Acta neuropathologica communications · 2026Article
- Analysis of Specific Serum Markers for Early Prediction of Alzheimer's Disease in Adolescents with Down Syndrome.Indian journal of clinical biochemistry : IJCB · 2025Article
- The Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and its contributions to understanding Alzheimer's disease in Down syndrome: A decade of discovery.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Exploring peripheral fluid biomarkers for early detection of Alzheimer's disease in Down syndrome: A literature review.Heliyon · 2025Review
- Gene-variant specific effects of plasma amyloid-β levels in Swedish autosomal dominant Alzheimer disease.Alzheimer's research & therapy · 2024Article
- Cognitive outcome measures for tracking Alzheimer's disease in Down syndrome.International review of research in developmental disabilities · 2022Article
- Alzheimer's disease associated with Down syndrome: a genetic form of dementia.The Lancet. Neurology · 2021Review
- The Clinical and Neuropathological Features of Sporadic (Late-Onset) and Genetic Forms of Alzheimer's Disease.Journal of clinical medicine · 2021Review
- Blood Biomarkers for Alzheimer's Disease in Down Syndrome.Journal of clinical medicine · 2021Review
- Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.The Lancet. Neurology · 2021Article
- Article
- Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials.CNS drugs · 2020Review
- Coping strategies adopted by Iranian families of children with Down syndrome: A qualitative study.Medicine · 2020Article
- Further understanding the connection between Alzheimer's disease and Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020Review
- Cerebrospinal fluid biomarkers of Alzheimer's disease in a cohort of adults with Down syndrome.Alzheimer's & dementia (Amsterdam, Netherlands) · 2020Article
- Distribution of microglial phenotypes as a function of age and Alzheimer's disease neuropathology in the brains of people with Down syndrome.Alzheimer's & dementia (Amsterdam, Netherlands) · 2020Article
- Exosome release and cargo in Down syndrome.Developmental neurobiology · 2019Review
- Dementia in Down syndrome: unique insights for Alzheimer disease research.Nature reviews. Neurology · 2019Review
- The proteome of neurofilament-containing protein aggregates in blood.Biochemistry and biophysics reports · 2018Article
- The Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) Scale: Comprehensive Assessment of Psychopathology in Down Syndrome.Journal of Alzheimer's disease : JAD · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Down syndrome (DS), present in nearly six million people, is associated with an extremely high risk to develop Alzheimer's disease (AD). Amyloid-β and tau pathology are omnipresent from age 40 years onward, but clinical symptoms do not appear in all DS individuals. Dementia diagnostics is complex in this population, illustrating the great need for predictive biomarkers. Although blood biomarkers have not yet proven useful, cerebrospinal fluid (CSF) biomarkers (low amyloid-β42, high t-tau, and high p-tau) effectively contribute to AD diagnoses in the general population and are increasingly used in clinical practice. Surprisingly, CSF biomarkers have been barely evaluated in DS. Breaking the taboo on CSF analyses would finally allow for the elucidation of its utility in (differential) diagnoses and staging of disease severity. A sensitive and specific biomarker profile for AD in DS would be of paramount importance to daily care, adaptive caregiving, and specific therapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.